3rd Next-Generation Conjugates Summit Hotel Commonwealth, Boston

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats
Traditional ADCs have seen significant success in recent years, but still face many challenges, from limited payload capacities to significant toxicities.

Given these limitations, drug developers are venturing beyond the conventional boundaries of conjugate drug design, by exploring novel payloads and targeting formats, with companies including VincerX Pharma, Dyne Therapeutics, and Orum Therapeutics currently awaiting clinical validation.

Join 150+ of your peers to share learnings and collaborate on novel design concepts, key translational and clinical development challenges, and address challenging CMC roadblocks for the next generation of conjugated therapeutics, including antibody-oligonucleotide conjugates, fragment-drug conjugates, antibody-degrader conjugates, small molecule-drug conjugates, and bispecific-drug conjugates and more!